SISCAPA Assay Technologies Appoints Gustavo Salem as President and CEO
News Apr 28, 2014
SISCAPA Assay Technologies, Inc. today announced the appointment of Gustavo (Gus) Salem to the position of President and CEO. For the past 18 months, Gus has served as a member of the board of directors and has worked closely with the company to evaluate strategic opportunities in the life science research and clinical diagnostics markets.
“We are extremely pleased to have Gus join the SAT team, and to drive our execution as a commercial stage company,” said Leigh Anderson, SAT’s founder, who continues as Chairman and Chief Scientific Officer. “Gus has already brought great value as an engaged board member based on a proven track-record in building teams, developing strategy and entering new markets. His familiarity with the company, technology and team will provide for a smooth and effective transition.”
Gus brings over 25 years of life science and health science leadership experience to the position. Previously, while VP and General Manager of the Biological Systems Division at Agilent Technologies, he managed the mass spectrometry, genomics, and clinical diagnostics businesses amounting to >$500M annual sales. During his tenure, Agilent developed into a market-leading supplier of LC/MS and established market leadership in target enrichment sample prep for next generation DNA sequencing. Gus previously served as President and CEO of Assay Designs, Inc., a venture-backed company developing immunoassays and antibody reagents (now part of Enzo Life Sciences). Prior to Assay Designs he managed the Protein Separations Division of Bio-Rad Laboratories, which included product lines for chromatography and electrophoresis instruments and consumables.
“I want to thank Leigh and my fellow board members for this opportunity. We have identified some very exciting new diagnostic opportunities, and will continue to invest in the analytical and clinical validation of SISCAPA technology. The company is committed to our current partners and customers in improving access to the technology, and expanding our customer base through launch of new products and services,” said Mr. Salem. “I am very excited to lead the team as we increase our focus on lab operations and commercial activities. We have great partners, strong revenue momentum, and an excellent strategy focused on empowering patients through improved clinical tests.”
Comments | 0 ADD COMMENT
Decoding Microbial Metabolism Explains Biofuel Yield
News Jan 20, 2017